MONOPAR THERAPEUTICS INC (MNPR) Stock Price, Quote, News and Overview
NASDAQ:MNPR - Nasdaq - US61023L2079 - Common Stock - Currency: USD
MNPR Quote, Performance and Key Statistics
NASDAQ:MNPR (4/24/2025, 12:10:50 PM)
42.92
+1.45 (+3.5%)
The current stock price of MNPR is 42.92 USD. In the past month the price increased by 10.35%. In the past year, price increased by 1160.1%.
MNPR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.88 | 320.15B | ||
| AMGN | AMGEN INC | 14.19 | 151.22B | ||
| GILD | GILEAD SCIENCES INC | 23.27 | 133.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1695.41 | 126.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.07 | 65.21B | ||
| ARGX | ARGENX SE - ADR | 324.73 | 36.88B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.61B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.99B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.59B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 25.91B | ||
| NTRA | NATERA INC | N/A | 20.64B | ||
| BIIB | BIOGEN INC | 7.28 | 17.55B |
Related stock screener links
About MNPR
Company Profile
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 10 full-time employees. The company went IPO on 2019-12-19. The firm is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The firm has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
Company Info
MONOPAR THERAPEUTICS INC
1000 Skokie Blvd Ste 350
Wilmette ILLINOIS 60091 US
CEO: Chandler Robinson
Employees: 10
Company Website: https://www.monopartx.com/
Investor Relations: http://ir.monopartx.com
Phone: 18473880349
MONOPAR THERAPEUTICS INC / MNPR FAQ
What is the stock price of MONOPAR THERAPEUTICS INC today?
The current stock price of MNPR is 42.92 USD. The price increased by 3.5% in the last trading session.
What is the ticker symbol for MONOPAR THERAPEUTICS INC stock?
The exchange symbol of MONOPAR THERAPEUTICS INC is MNPR and it is listed on the Nasdaq exchange.
On which exchange is MNPR stock listed?
MNPR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MONOPAR THERAPEUTICS INC stock?
10 analysts have analysed MNPR and the average price target is 48.45 USD. This implies a price increase of 12.88% is expected in the next year compared to the current price of 42.92. Check the MONOPAR THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MONOPAR THERAPEUTICS INC worth?
MONOPAR THERAPEUTICS INC (MNPR) has a market capitalization of 262.24M USD. This makes MNPR a Micro Cap stock.
How many employees does MONOPAR THERAPEUTICS INC have?
MONOPAR THERAPEUTICS INC (MNPR) currently has 10 employees.
What are the support and resistance levels for MONOPAR THERAPEUTICS INC (MNPR) stock?
MONOPAR THERAPEUTICS INC (MNPR) has a support level at 31.27 and a resistance level at 44.75. Check the full technical report for a detailed analysis of MNPR support and resistance levels.
Should I buy MONOPAR THERAPEUTICS INC (MNPR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MNPR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MNPR, evaluating the profitability, health, valuation and growth aspects
- MONOPAR THERAPEUTICS INC (MNPR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MONOPAR THERAPEUTICS INC (MNPR) Sales and EPS estimates to see what analysts future expectations are.
- MONOPAR THERAPEUTICS INC (MNPR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MONOPAR THERAPEUTICS INC (MNPR) Insider and Institutional Ownership to learn about the owners and their transactions.
- MONOPAR THERAPEUTICS INC (MNPR) Stock Chart to make your own analysis
- MONOPAR THERAPEUTICS INC (MNPR) Latest news and press-releases to stay up to date.
Does MONOPAR THERAPEUTICS INC (MNPR) stock pay dividends?
MNPR does not pay a dividend.
When does MONOPAR THERAPEUTICS INC (MNPR) report earnings?
MONOPAR THERAPEUTICS INC (MNPR) will report earnings on 2025-05-09.
What is the Price/Earnings (PE) ratio of MONOPAR THERAPEUTICS INC (MNPR)?
MONOPAR THERAPEUTICS INC (MNPR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.12).
What is the Short Interest ratio of MONOPAR THERAPEUTICS INC (MNPR) stock?
The outstanding short interest for MONOPAR THERAPEUTICS INC (MNPR) is 1.29% of its float. Check the ownership tab for more information on the MNPR short interest.
MNPR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MNPR. When comparing the yearly performance of all stocks, MNPR is one of the better performing stocks in the market, outperforming 99.9% of all stocks.
MNPR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MNPR. No worries on liquidiy or solvency for MNPR as it has an excellent financial health rating, but there are worries on the profitability.
MNPR Financial Highlights
Over the last trailing twelve months MNPR reported a non-GAAP Earnings per Share(EPS) of -4.12. The EPS decreased by -35.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.85% | ||
| ROE | -28.32% | ||
| Debt/Equity | 0 |
MNPR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to MNPR. The Buy consensus is the average rating of analysts ratings from 10 analysts.